STOCK TITAN

Vertex (VRTX) CMO granted stock; shares withheld for taxes

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vertex Pharmaceuticals EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock as a restricted stock unit award that begins vesting on February 20, 2027. On the same date, 1,912 shares at $483.75 each were disposed of to cover tax withholding, leaving her with 41,516 directly owned shares.

Positive

  • None.

Negative

  • None.
Insider Bozic Carmen
Role EVP and CMO
Type Security Shares Price Value
Grant/Award Common Stock 5,375 $0.00 --
Tax Withholding Common Stock 1,912 $483.75 $925K
Holdings After Transaction: Common Stock — 43,428 shares (Direct)
Footnotes (1)
  1. [object Object]
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bozic Carmen

(Last) (First) (Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE

(Street)
BOSTON MA 02210

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP and CMO
3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/17/2026 A 5,375(1) A $0 43,428 D
Common Stock 02/17/2026 F 1,912 D $483.75 41,516 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted stock unit award that vests in installments beginning on February 20, 2027.
Remarks:
/s/ Christiana Stevenson, Attorney-in-Fact 02/19/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Vertex (VRTX) report for Carmen Bozic?

Vertex reported that EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock and disposed of 1,912 shares for tax withholding. After these transactions, she directly owned 41,516 shares of Vertex common stock.

Was the Vertex (VRTX) insider transaction by Carmen Bozic a stock award?

Yes. Carmen Bozic received a 5,375-share restricted stock unit award of Vertex common stock. According to the disclosure, this award will vest in installments beginning on February 20, 2027, reflecting equity-based compensation rather than an open-market stock purchase.

Why were 1,912 Vertex (VRTX) shares disposed of in Carmen Bozic’s Form 4?

The 1,912 shares were disposed of to satisfy tax withholding obligations. The filing identifies the transaction with code “F,” meaning payment of tax liability by delivering securities, at a price of $483.75 per share, rather than an ordinary open-market sale.

How many Vertex (VRTX) shares does Carmen Bozic own after the reported transactions?

After the reported Form 4 transactions, Carmen Bozic directly owns 41,516 shares of Vertex common stock. This figure reflects the new restricted stock unit award and the shares disposed of to cover related tax withholding obligations on February 17, 2026.

When do Carmen Bozic’s new Vertex (VRTX) restricted stock units begin vesting?

The restricted stock unit award granted to Carmen Bozic begins vesting on February 20, 2027. The footnote explains that the 5,375-share award will vest in installments starting on that date, consistent with typical long-term incentive compensation structures.